A Switch Therapy for Community-acquired Pneumonia: A Randomized Controlled Trial

Phase 4

• Conditions: Community-acquired pneumonia in adults

• Registration Number: JPRN-UMIN000002096
• Lead Sponsor: agasaki evaluation organization for clinical interventions

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-01
• Study Completion: 2010-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with episodes of aspiration 2) Patients with thoracic cavity drainage due to lung suppuration or empyema 3) Obstructive pneumonia due to airway obstruction 4) Legionella, MRSA, and P. aeruginosa are causative microorganism. 5) Patients who are treated with more than 10 mg of steroid 6) Patients with infections due to causative microorganism which is regarded as being ineffective to garenoxacin 7) Patients with a history of allergy/severe adverse effect to quinolone antibacterial agents or B-lactum antibacterial agents 8) Patients with a history of seizure/epilepsy or patients who are taking antiepilepsy drug 9) Patients with severe hepatic impairment, renal impairment, and cardiac impairment 10) Pregnancy/lactation 11) Patients who are regarded as inadequate subject by physician in charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical and bacteriologic efficacy, chest radiograph resolution, and patient satisfaction in oral therapy and parenteral therapy.

Secondary Outcome Measures

Name	Time	Method
Analysis of the cost-effectiveness of oral therapy and parenteral therapy.